Abstract | BACKGROUND: METHODS: RESULTS: Overall response rate was 43.5% in patients treated with monotherapy and 51.3% with combination therapy (p = 0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months versus 6 months; p = 0.05), 1-year progression-free survival rate (43.2% versus 21.7%; p = 0.05), median overall survival (29.7 months versus 22 months; p = 0.05), and 2-year survival rate (64.9% versus 43.5%; p = 0.05). CONCLUSIONS:
|
Authors | Luigi Di Lauro, Laura Pizzuti, Maddalena Barba, Domenico Sergi, Isabella Sperduti, Marcella Mottolese, Carla Azzurra Amoreo, Franca Belli, Patrizia Vici, Valerie Speirs, Daniele Santini, Ruggero De Maria, Marcello Maugeri-Saccà |
Journal | Journal of hematology & oncology
(J Hematol Oncol)
Vol. 8
Pg. 53
(May 17 2015)
ISSN: 1756-8722 [Electronic] England |
PMID | 25980944
(Publication Type: Journal Article)
|
Chemical References |
- Aromatase Inhibitors
- Gonadotropin-Releasing Hormone
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Aromatase Inhibitors
(metabolism)
- Breast Neoplasms, Male
(drug therapy)
- Female
- Gonadotropin-Releasing Hormone
(analogs & derivatives)
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Young Adult
|